Adjuvant formulations and delivery systems for DNA vaccines.
about
Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits.Overlapping binding sites in protein phosphatase 2A for association with regulatory A and alpha-4 (mTap42) subunits.Phosphorylation-dependent autoinhibition of myosin light chain phosphatase accounts for Ca2+ sensitization force of smooth muscle contractionGene therapy progress and prospects: electroporation and other physical methods.Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccineSkin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.IFN-gamma increases efficiency of DNA vaccine in protecting ducks against infectionSystemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines.Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses.Strategies for DNA vaccine delivery.Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporationImmune-Enhancing Effects of Taishan Pinus massoniana Pollen Polysaccharides on DNA Vaccine Expressing Bordetella avium ompA.Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responsesImmune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania majorThe effect of the nonionic block copolymer pluronic P85 on gene expression in mouse muscle and antigen-presenting cells.Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.DNA vaccines: roles against diseases.Novel adjuvants & delivery vehicles for vaccines development: a road aheadDNA vaccines: a rational design against parasitic diseases.Co-administration of vaccination with DNA encoding T cell epitope on the Der p and BCG inhibited airway remodeling in a murine model of chronic asthma.DNA-based influenza vaccines as immunoprophylactic agents toward universality.The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccineInduction of a robust immune response against avian influenza virus following transdermal inoculation with H5-DNA vaccine formulated in modified dendrimer-based delivery system in mouse model.Comparing the effect of IL-12 genetic adjuvant and alum non-genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of Toxoplasma gondii.Induction of Immune Responses by DNA Vaccines Formulated with Dendrimer and Poly (Methyl Methacrylate) (PMMA) Nano-Adjuvants in BALB/c Mice Infected with Leishmania major.
P2860
Q24562656-F8B37989-BCC9-4A59-9DCB-E0AC35E0BEF1Q30433957-EB1CDDCF-728C-4786-BE7B-E92F17902A28Q30435173-E09A0FDD-9E87-4FC4-94D0-77F58A3A67BCQ31104973-E7773DD1-A864-4371-85FF-0CC4DE35FB9EQ33781642-D6DE09E4-3E06-45C7-82CA-5CF44ED1127EQ34801021-5B5CAFE8-3233-4B26-87B6-77F1E92143F6Q35064484-0B34EE02-B4A6-45E6-B7D7-285991E68CEFQ35417954-8927766C-A347-4D0C-89C9-8F4B6F2B1F50Q36256253-DAA0A739-A340-482F-9AB2-16269675EE50Q36316818-F07A9FDA-8050-4095-8093-12F444B39BD0Q36428352-E6862A3C-F89B-477C-9402-BD11548F05E0Q36527749-48B346FE-3BE8-4E8B-B61B-C97FBA87EBEFQ36972226-03B80C41-F0A8-48FC-895F-62E442CBC04BQ37053209-19589B6E-3EC9-41D4-B3BC-BB215970DBBCQ37155956-15A468C5-94AE-4A07-ADE2-F7C21C328919Q37351412-FCDF1B03-F68B-4B67-A0F7-C79571411DD2Q37441566-E124563A-293F-49EC-A38E-C737D2E7066DQ37592383-41625DC5-D06E-4219-A6CA-0EDB2ACC7D9EQ37682900-E94CE54F-20FE-4BA0-9AD2-D413D868DBBCQ38509766-AEFDE387-0CE2-4DE3-B0C6-34D86E814F97Q38670879-8995093B-5D54-46C2-B622-53823708A487Q41278156-A94F9E79-B166-4719-911D-810E2DD5F3A8Q47136368-923D4BAA-7454-40F6-BBE0-7D2753445F4CQ51358760-2841F7D1-EE7C-4D21-837A-33D83A0E8A54Q52659333-C1FB2BCB-5C6D-47B6-9666-A1E42C95A05A
P2860
Adjuvant formulations and delivery systems for DNA vaccines.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Adjuvant formulations and delivery systems for DNA vaccines.
@ast
Adjuvant formulations and delivery systems for DNA vaccines.
@en
type
label
Adjuvant formulations and delivery systems for DNA vaccines.
@ast
Adjuvant formulations and delivery systems for DNA vaccines.
@en
prefLabel
Adjuvant formulations and delivery systems for DNA vaccines.
@ast
Adjuvant formulations and delivery systems for DNA vaccines.
@en
P2093
P1433
P1476
Adjuvant formulations and delivery systems for DNA vaccines.
@en
P2093
Fumihiko Takeshita
Ke Qin Xin
Kenji Okuda
Norihisa Ishii
Shin Sasaki
P304
P356
10.1016/S1046-2023(03)00140-3
P577
2003-11-01T00:00:00Z